You are here: Industry Insights > InnoCare

News List

InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH prnasia
November 09, 2021
InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company will present latest data of its BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH)...
InnoCare Announces Approval of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China prnasia
October 19, 2021
InnoCare Pharma (HKEX: 09969) announced today that the Company has received Investigational New Drug (IND) approval from the NMPA for its SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189...
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP in China prnasia
August 11, 2021
InnoCare Pharma, a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) for starting ...
Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis drugs
July 16, 2021
Biogen Inc. (Nasdaq: BIIB) and InnoCare Pharma Limited (HKEX: 09969) today announced that they have entered into a license and collaboration agreement for orelabrutinib, an oral small molecule Bruton’s tyrosine kinase inhibitor (BTKi)
Biogen pays $125 million upfront for rights to InnoCare's orelabrutinib in MS deal firstwordpharma
July 13, 2021
Biogen has agreed to pay InnoCare Pharma $125 million upfront for exclusive rights to the oral BTK inhibitor orelabrutinib for the potential treatment of multiple sclerosis (MS) worldwide and certain autoimmune diseases outside of China.
InnoCare Announces Approval of Initiation of Phase 1 Clinical Trial of RTK Inhibitor ICP-033 in China prnasia
June 28, 2021
InnoCare, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced that China's National Medical Products Administration (NMPA) has approved the initiation of a Phase I clinical trial of ICP-033, the Company's novel ...
InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL prnasia
June 28, 2021
InnoCare Pharma, a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment ...
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma prnasia
June 21, 2021
InnoCare announced the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib at the 16th International Conference on Malignant Lymphoma (ICML).
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on MPresents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma prnasia
June 18, 2021
InnoCare announced today the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib at the 16th International Conference on Malignant Lymphoma (ICML).
InnoCare Announces Orphan Drug Designation of Gunagrabtinib by US FDA for Treatment of Cholangiocarcinoma prnasia
June 17, 2021
InnoCare, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its pan-FGFR inhibitor gunagratinib (ICP-192) for the ...

Previous page 1 2 3 4 5 6 7 Next page